Mirati Therapeutics shares tumble on release of Phase 2 trial data for lung cancer treatment
Shares of the biotech company Mirati Therapeutics (NASDAQ:MRTX) are slipping on the release of Phase 2 clinical data for its combination drug treating lung cancer.
The study was evaluating Mirati’s therapy sitravatinib in combination with Bristol-Myers Squibb Co’s (NYSE:BMY) groundbreaking drug Opdivo as a method for treating non-small cell lung cancer.
Sitravatinib is a small molecule tyrosine kinase inhibitor that is currently being evaluated in three clinical development programs for the treatment of genetically-defined lung cancer and other solid tumors.
Out of 56 patients, 16 of those taking part in the Phase 2 study achieved either a partial or complete response rate to the treatment. While 45 of 56 patients saw their tumors shrink, 18 of 56 patients reported a more than 30% reduction in the size of their tumors.
Investors came away unimpressed with the results, however, sending Mirati shares down 18.4% to $32.65 in Monday’s afternoon trading session.
READ: Bristol-Myers Squibb shares fall after FDA delays approval for lung cancer therapy
But in response, Oppenheimer analyst Leah Rush Cann is sticking to an Outperform rating on the company’s stock with a $62 price target.
“We find these results encouraging and supportive of sitravatinib as a combination therapy with a checkpoint inhibitor,” Rush Cann writes in a note to investors.
The analyst is projecting that sitravatinib could launch in 2023 as both a single agent and in combination with other agents and could account for nearly 34% of Mirati’s estimated product sales.
Mirati plans to launch a Phase 3 study in patients with non-small cell lung cancer who have already received initial treatments that compares the combination of sitravatinib plus a checkpoint inhibitor to docetaxel in the first half of next year.
The company is a clinical-stage oncology company based in San Diego, California.
Contact Ellen Kelleher at [email protected]
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/207600/mirati-therapeutics-shares-tumble-on-release-of-phase-2-trial-data-for-lung-cancer-treatment-207600.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).